Disease-A-Month
Volume 54, Issue 7 , Pages 486-507 , July 2008

Care of the Liver Transplant Patient

References 

  1. McCashland TM. Posttransplantation care: role of the primary care physician versus transplant center. Liver Transplant. 2001;7:S2–S12
  2. Roberts MS, Angus DC, Bryce CL, et al. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transplant. 2004;10:886–897
  3. Schrem H, Luck R, Becker T, et al. Update on liver transplantation using cyclosporine. Transplant Proc. 2004;36:2525–2531
  4. Post DJ, Douglas DD, Mulligan DC. Immunosuppression in liver transplantation. Liver Transplant. 2005;11:1307–1314
  5. Komolmit P, Davies MH. Tacrolimus in liver transplantation. Exp Opin Invest Drugs. 1999;8:1239–1254
  6. Fulton B, Markham A. Mycophenolate mofetil (A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation). Drugs. 1996;51:278–298
  7. Fung J, Kelly D, Kadry Z, et al. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transplant. 2005;11:267–280
  8. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80:883–889
  9. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation. 2007;83:1162–1168
  10. Soin AS, Rasmussen A, Jamieson NV, et al. CsA levels in the early posttransplant period–predictive of chronic rejection in liver transplantation?. Transplantation. 1995;27:1119–1123
  11. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 1998;28:638–645
  12. Ramji A, Yoshida EM, Bain VG, et al. Late acute rejection after liver transplantation: the Western Canada experience. Liver Transplant. 2002;8:945–951
  13. Wiesner RH. Advances in diagnosis, prevention, and management of hepatic allograft rejection. Clin Chem. 1994;40:2174–2185
  14. Wiesner RH, Ludwig J, van Hoek B, et al. Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology. 1991;14:721–729
  15. Klintmalm GB, Nery JR, Husberg BS, et al. Rejection in liver transplantation. Hepatology. 1989;10:978–985
  16. Neuberger J, Adams DH. What is the significance of acute liver allograft rejection?. J Hepatol. 1998;29:143–150
  17. Dousset B, Conti F, Cherruau B, et al. Is acute rejection deleterious to long-term liver allograft function?. J Hepatol. 1998;29:660–668
  18. Adams DH, Neuberger JM. Patterns of graft rejection following liver transplantation. J Hepatol. 1990;10:113–119
  19. Mor E, Gonwa TA, Husberg BS, et al. Late-onset acute rejection in orthotopic liver transplantation: associated risk factors and outcome. Transplantation. 1992;54:821–824
  20. Ludwig J. Terminology of hepatic allograft rejection (glossary). Semin Liver Dis. 1992;12:89–92
  21. Ludwig J, Wiesner RH, Batts KP, et al. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology. 1987;7:476–483
  22. Pirsch JD, Kalayoglu M, Hafez GR, et al. Evidence that the vanishing bile duct syndrome is vanishing. Transplantation. 1990;49:1015–1018
  23. Batts KP. Acute and chronic hepatic allograft rejection: pathology and classification. Liver Transplant Surg. 1999;5:S21–S29
  24. Park JS, Kim MH, Lee SK, et al. Efficacy of endoscopic and percutaneous treatments for biliary complications after cadaveric and living donor liver transplantation. Gastrointest Endosc. 2003;57:78–85
  25. Qian YB, Liu CL, Lo CM, et al. Risk factors for biliary complications after liver transplantation. Arch Surg. 2004;139:1101–1105
  26. Rerknimitr R, Sherman S, Fogel EL, et al. Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. Gastrointest Endosc. 2002;55:224–231
  27. Sawyer RG, Punch JD. Incidence and management of biliary complications after 291 liver transplants following the introduction of transcystic stenting. Transplantation. 1998;66:1201–1207
  28. Thethy S, Thomson B, Pleass H, et al. Management of biliary tract complications after orthotopic liver transplantation. Clin Transplant. 2004;18:647–653
  29. Greif F, Bronsther OL, Van Thiel DH, et al. The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg. 1994;219:40–45
  30. Moser MA, Wall WJ. Management of biliary problems after liver transplantation. Liver Transplant. 2001;7:S46–S52
  31. Scatton O, Meunier B, Cherqui D, et al. Randomized trial of choledochocholedochostomy with or without a T tube in orthotopic liver transplantation. Ann Surg. 2001;233:432–437
  32. Vougas V, Rela M, Gane E, et al. A prospective randomised trial of bile duct reconstruction at liver transplantation: T tube or no T tube?. Transplant Int. 1996;9:392–395
  33. Tung BY, Kimmey MB. Biliary complications of orthotopic liver transplantation. Dig Dis. 1999;17:133–144
  34. Hampe T, Dogan A, Encke J, et al. Biliary complications after liver transplantation. Clin Transplant. 2006;20(suppl 17):93–96
  35. Verdonk RC, Buis CI, Porte RJ, et al. Biliary complications after liver transplantation: a review. Scand J Gastroenterol. 2006;243:89–101
  36. Jagannath S, Kalloo AN. Biliary complications after liver transplantation. Curr Treat Options Gastroenterol. 2002;5:101–112
  37. Morelli J, Mulcahy HE, Willner IR, et al. Long-term outcomes for patients with post-liver transplant anastomotic biliary strictures treated by endoscopic stent placementj. Gastrointest Endosc. 2003;58:374–379
  38. Mahajani RV, Cotler SJ, Uzer MF. Efficacy of endoscopic management of anastomotic biliary strictures after hepatic transplantation. Endoscopy. 2000;32:943–949
  39. Moench C, Moench K, Lohse AW, et al. Prevention of ischemic-type biliary lesions by arterial back-table pressure perfusion. Liver Transplant. 2003;9:285–289
  40. Parry SD, Muiesan P. Cholangiopathy and the biliary cast syndrome. Eur J Gastroenterol Hepatol. 2003;15:341–343
  41. Barton P, Steininger R, Maier A, et al. Biliary sludge after liver transplantation (II. Treatment with interventional techniques versus surgery and/or oral chemolysis). AJR Am J Roentgenol. 1995;164:865–869
  42. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant. 2004;4(suppl 10):160–163
  43. Iinuma Y, Senda K, Fujihara N, et al. Surgical site infection in living-donor liver transplant recipients: a prospective study. Transplantation. 2004;78:704–709
  44. Petri JB, Schurk S, Gebauer S, et al. Cyclosporine A delays wound healing and apoptosis and suppresses activin beta-A expression in rats. Eur J Dermatol. 1998;8:104–113
  45. Stephan RN, Munschauer CE, Kumar MS. Surgical wound infection in renal transplantation: outcome data in 102 consecutive patients without perioperative systemic antibiotic coverage. Arch Surg. 1997;132:1315–1318
  46. Singh N. Infectious diseases in the liver transplant recipient. Semin Gastrointest Dis. 1998;9:136–146
  47. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338:1741–1751
  48. Shibolet O, Ilan Y, Kalish Y, et al. Late cytomegalovirus disease following liver transplantation. Transplant Int. 2003;16:861–865
  49. Singh N, Muder RR, Yu VL, et al. Legionella infection in liver transplant recipients: implications for management. Transplantation. 1993;56:1549–1551
  50. Singh N, Gayowski T, Wagener M, et al. Pulmonary infections in liver transplant recipients receiving tacrolimus (Changing pattern of microbial etiologies). Transplantation. 1996;61:396–401
  51. Mizuno S, Zendejas IR, Reed AI, et al. Listeria monocytogenes following orthotopic liver transplantation: central nervous system involvement and review of the literature. World J Gastroenterol. 2007;13:4391–4393
  52. Wu G, Vilchez RA, Eidelman B, et al. Cryptococcal meningitis: an analysis among 5,521 consecutive organ transplant recipients. Transplant Infect Dis. 2002;4:183–188
  53. Laryea M, Watt KD, Molinari M, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transplant. 2007;13:1109–1114
  54. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  55. Sawyer RG, Pelletier SJ, Pruett TL. Increased early morbidity and mortality with acceptable long-term function in severely obese patients undergoing liver transplantation. Clin Transplant. 1999;13:126–130
  56. Munoz SJ, Deems RO, Moritz MJ, et al. Hyperlipidemia and obesity after orthotopic liver transplantation. Transplant Proc. 1991;23:1480–1483
  57. Stegall MD, Everson G, Schroter G, et al. Metabolic complications after liver transplantation (Diabetes, hypercholesterolemia, hypertension, and obesity). Transplantation. 1995;60:1057–1060
  58. Canzanello VJ, Schwartz L, Taler SJ, et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transplant Surg. 1997;3:1–9
  59. Richards J, Gunson B, Johnson J, et al. Weight gain and obesity after liver transplantation. Transplant Int. 2005;18:461–466
  60. Navasa M, Bustamante J, Marroni C, et al. Diabetes mellitus after liver transplantation: prevalence and predictive factors. J Hepatol. 1996;25:64–71
  61. John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transplant. 2002;8:708–713
  62. Steinmuller TH, Stockmann M, Bechstein WO, et al. Liver transplantation and diabetes mellitus. Exp Clin Endocrinol Diabetes. 2000;108:401–405
  63. Baid S, Cosimi AB, Farrell ML, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation. 2001;72:1066–1072
  64. AlDosary AA, Ramji AS, Elliott TG, et al. Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transplant. 2002;8:356–361
  65. Tueche SG. Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding. Transplant Proc. 2003;35:1466–1468
  66. Cotler SJ, Kallwitz E, TenCate V, et al. Diabetes and hepatic oxidative damage are associated with hepatitis C progression after liver transplantation. Transplantation. 2007;84:587–591
  67. Foxton MR, Quaglia A, Muiesan P, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2006;6:1922–1929
  68. Canzanello VJ, Textor SC, Taler SJ, et al. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transplant Surg. 1998;4:328–334
  69. Sheiner PA, Magliocca JF, Bodian CA, et al. Long-term medical complications in patients surviving ≥5 years after liver transplant. Transplantation. 2000;69:781–789
  70. Rabkin JM, Corless CL, Rosen HR, et al. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg. 2002;183:595–599
  71. Neal DA, Brown MJ, Wilkinson IB, et al. Mechanisms of hypertension after liver transplantation. Transplantation. 2005;79:935–940
  72. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation (The US Multicenter FK506 Liver Study Group). N Engl J Med. 1994;331:1110–1115
  73. Lerman A, Click RL, Narr BJ, et al. Elevation of plasma endothelin associated with systemic hypertension in humans following orthotopic liver transplantation. Transplantation. 1991;51:646–650
  74. Guckelberger O, Bechstein WO, Neuhaus R, et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant. 1997;11:60–65
  75. Gisbert C, Prieto M, Berenguer M, et al. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transplant Surg. 1997;3:416–422
  76. Charco R, Cantarell C, Vargas V, et al. Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy. Liver Transplant Surg. 1999;5:204–208
  77. Manzarbeitia C, Reich DJ, Rothstein KD, et al. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. Liver Transplant. 2001;7:93–99
  78. Trotter JF, Wachs ME, Trouillot TE, et al. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transplant. 2001;7:401–408
  79. Zachoval R, Gerbes AL, Schwandt P, et al. Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial. J Hepatol. 2001;35:86–91
  80. Broeders N, Knoop C, Antoine M, et al. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?. Nephrol Dial Transplant. 2000;15:1993–1999
  81. Abbasoglu O, Levy MF, Brkic BB, et al. Ten years of liver transplantation: an evolving understanding of late graft loss. Transplantation. 1997;64:1801–1807
  82. Giannini S, Nobile M, Dalle Carbonare L, et al. Vertebral morphometry by X-ray absorptiometry before and after liver transplant: a cross-sectional study. Eur J Gastroenterol Hepatol. 2001;13:1201–1207
  83. Figueiredo FA, Brandao C, Perez Rde M, et al. Low bone mineral density in noncholestatic liver cirrhosis: prevalence, severity and prediction. Arq Gastroenterol. 2003;40:152–158
  84. Guichelaar MM, Malinchoc M, Sibonga J, et al. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology. 2002;36:895–903
  85. Hodgson SF, Dickson ER, Wahner HW, et al. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med. 1985;103:855–860
  86. Monegal A, Navasa M, Guanabens N, et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int. 1997;60:148–154
  87. McCaughan GW, Feller RB. Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Dig Dis. 1994;12:223–231
  88. Eastell R, Dickson ER, Hodgson SF, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology. 1991;14:296–300
  89. McDonald JA, Dunstan CR, Dilworth P, et al. Bone loss after liver transplantation. Hepatology. 1991;14:613–619
  90. Gonwa TA, Morris CA, Goldstein RM, et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients. Transplantation. 1991;51:428–430
  91. Gonwa TA. Hypertension and renal dysfunction in long-term liver transplant recipients. Liver Transplant. 2001;7:S22–S26
  92. Andoh TF, Burdmann EA, Bennett WM. Nephrotoxicity of immunosuppressive drugs: experimental and clinical observations. Semin Nephrol. 1997;17:34–45
  93. Kopp JB, Klotman PE. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol. 1990;1:162–179
  94. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326–2333
  95. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transplant. 2003;9:741–747
  96. Reich D, Rothstein K, Manzarbeitia C, et al. Common medical diseases after liver transplantation. Semin Gastrointest Dis. 1998;9:110–125
  97. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001;72:1934–1939
  98. Fisher NC, Nightingale PG, Gunson BK, et al. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation. 1998;66:59–66
  99. Kim DY, Lim C, Parasuraman R, et al. Renal disease burden following liver transplantation. Transplant Proc. 2006;38:3663–3665
  100. Jain AB, Yee LD, Nalesnik MA, et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation. 1998;66:1193–1200
  101. Sheil AG. Malignancy following liver transplantation: a report from the Australian Combined Liver Transplant Registry. Transplant Proc. 1995;27:1247
  102. Kelly DM, Emre S, Guy SR, et al. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer. 1998;83:1237–1243
  103. Levy M, Backman L, Husberg B, et al. De novo malignancy following liver transplantation: a single-center study. Transplant Proc. 1993;25:1397–1399
  104. Jain A, DiMartini A, Kashyap R, et al. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation. 2000;70:1335–1342
  105. Berenguer M, Prieto M, Bustamante M, et al. [Incidence of de novo neoplasms after liver transplantation]. Med Clin. 1998;111:481–484
  106. Xiol X, Guardiola J, Menendez S, et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transplant. 2001;7:971–975
  107. Yao FY, Gautam M, Palese C, et al. De novo malignancies following liver transplantation: a case-control study with long-term follow-up. Clin Transplant. 2006;20:617–623
  108. Nalesnik MA. Lymphoproliferative disease in organ transplant recipients. Springer Semin Immunopathol. 1991;13:199–216
  109. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol. 1988;133:173–192
  110. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation. 2003;76:1289–1293
  111. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant. 2004;4:87–93
  112. Kremers WK, Devarbhavi HC, Wiesner RH, et al. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant. 2006;6:1017–1024
  113. Vallejo GH, Romero CJ, de Vicente JC. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol. 2005;56:87–99
  114. Ben-Ari Z, Amlot P, Lachmanan SR, et al. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome. Liver Transplant Surg. 1999;5:184–191
  115. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1:583–587
  116. McCarthy M, Ramage J, McNair A, et al. The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients. J Hepatol. 1997;27:1015–1021
  117. Norin S, Kimby E, Ericzon BG, et al. Posttransplant lymphoma: a single-center experience of 500 liver transplantations. Med Oncol. 2004;21:273–284
  118. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia (A follow-up study). Transplantation. 1996;61:715–721
  119. Perera GK, Child FJ, Heaton N, et al. Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients. Br J Dermatol. 2006;154:868–872
  120. Jimenez-Romero C, Manrique Municio A, Marques Medina E, et al. Incidence of de novo nonmelanoma skin tumors after liver transplantation for alcoholic and nonalcoholic liver diseases. Transplant Proc. 2006;38:2505–2507
  121. Herrero JI, Espana A, Quiroga J, et al. Nonmelanoma skin cancer after liver transplantation (Study of risk factors). Liver Transplant. 2005;11:1100–1106
  122. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc. 1995;27:1767–1768
  123. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681–1691
  124. Mithoefer AB, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transplant. 2002;8:939–944
  125. Duvoux C, Delacroix I, Richardet JP, et al. Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis. Transplantation. 1999;67:418–421
  126. Jimenez C, Manrique A, Marques E, et al. Incidence and risk factors for the development of lung tumors after liver transplantation. Transplant Int. 2007;20:57–63
  127. Jimenez C, Marques E, Manrique A, et al. Incidence and risk factors of development of lung tumors after liver transplantation. Transplant Proc. 2005;37:3970–3972
  128. Bleday R, Lee E, Jessurun J, et al. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum. 1993;36:908–912
  129. Silva MA, Jambulingam PS, Mirza DF. Colorectal cancer after orthotopic liver transplantation. Crit Rev Oncol Hematol. 2005;56:147–153
  130. Chazouilleres O, Kim M, Combs C, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology. 1994;106:994–999
  131. Ferrell LD, Wright TL, Roberts J, et al. Hepatitis C viral infection in liver transplant recipients. Hepatology. 1992;16:865–876
  132. Feray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C (European Concerted Action on Viral Hepatitis (EUROHEP) Group). Gastroenterology. 1999;117:619–625
  133. Ghobrial RM, Farmer DG, Baquerizo A, et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg. 1999;229:824–831
  134. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999;29:250–256
  135. Testa G, Crippin JS, Netto GJ, et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transplant. 2000;6:553–561
  136. Velidedeoglu E, Mange KC, Frank A, et al. Factors differentially correlated with the outcome of liver transplantation in hcv+ and HCV− recipients. Transplantation. 2004;77:1834–1842
  137. Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transplant. 2007;13:219–226
  138. Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation. 2004;77:226–231
  139. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889–896
  140. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation. 2004;77:190–194
  141. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology. 2005;41:289–298
  142. Eisenbach C, Sauer P, Mehrabi A, et al. Prevention of hepatitis B virus recurrence after liver transplantation. Clin Transplant. 2006;20(suppl 17):111–116
  143. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998;28:585–589
  144. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transplant. 2006;12:1813–1824
  145. Khalaf H, Mourad W, El-Sheikh Y, et al. Liver transplantation for autoimmune hepatitis: a single-center experience. Transplant Proc. 2007;39:1166–1170
  146. Lohse AW, Weiler-Norman C, Burdelski M. De novo autoimmune hepatitis after liver transplantation. Hepatol Res. 2007;37(suppl 3):S462
  147. Liermann Garcia RF, Evangelista Garcia C, McMaster P, et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology. 2001;33:22–27
  148. Guy JE, Qian P, Lowell JA, et al. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transplant. 2005;11:1252–1257
  149. Sylvestre PB, Batts KP, Burgart LJ, et al. Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history. Liver Transplant. 2003;9:1086–1093
  150. Khettry U, Anand N, Faul PN, et al. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transplant. 2003;9:87–96
  151. Schmitz V, Neumann UP, Puhl G, et al. Surgical complications and long-term outcome of different biliary reconstructions in liver transplantation for primary sclerosing cholangitis-choledochoduodenostomy versus choledochojejunostomy. Am J Transplant. 2006;6:379–385
  152. Brandsaeter B, Schrumpf E, Bentdal O, et al. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transplant. 2005;11:1361–1369
  153. Everson G, Bharadhwaj G, House R, et al. Long-term follow-up of patients with alcoholic liver disease who underwent hepatic transplantation. Liver Transplant Surg. 1997;3:263–274
  154. DiMartini A, Day N, Dew MA, et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transplant. 2006;12:813–820
  155. Tome S, Lucey MR. Timing of liver transplantation in alcoholic cirrhosis. J Hepatol. 2003;39:302–307
  156. Kowdley KV, Hassanein T, Kaur S, et al. Primary liver cancer and survival in patients undergoing liver transplantation for hemochromatosis. Liver Transplant Surg. 1995;1:237–241
  157. Tung BY, Farrell FJ, McCashland TM, et al. Long-term follow-up after liver transplantation in patients with hepatic iron overload. Liver Transplant Surg. 1999;5:369–374
  158. Farrell FJ, Nguyen M, Woodley S, et al. Outcome of liver transplantation in patients with hemochromatosis. Hepatology. 1994;20:404–410
  159. Kowdley KV, Brandhagen DJ, Gish RG, et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology. 2005;129:494–503
  160. Powell LW. Hemochromatosis: the impact of early diagnosis and therapy. Gastroenterology. 1996;110:1304–1307
  161. Kotlyar DS, Campbell MS, Reddy KR. Recurrence of diseases following orthotopic liver transplantation. Am J Gastroenterol. 2006;101:1370–1378
  162. Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transplant. 2001;7:608–614
  163. Groth CG, Dubois RS, Corman J, et al. Metabolic effects of hepatic replacement in Wilson's disease. Transplant Proc. 1973;5:829–833
  164. Filipponi F, Soubrane O, Labrousse F, et al. Liver transplantation for end-stage liver disease associated with alpha-1-antitrypsin deficiency in children: pretransplant natural history, timing and results of transplantation. J Hepatol. 1994;20:72–78
  165. Cundy TF, O'Grady JG, Williams R. Recovery of menstruation and pregnancy after liver transplantation. Gut. 1990;31:337–338
  166. Framarino Dei Malatesta M, Rossi M, Rocca B, et al. Fertility following solid organ transplantation. Transplant Proc. 2007;39:2001–2004
  167. Armenti VT, Radomski JS, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transplant. 2005;69–83
  168. Christopher V, Al-Chalabi T, Richardson PD, et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transplant. 2006;12:1138–1143
  169. Jabiry-Zieniewicz Z, Bobrowska K, Kaminski P, et al. Low-dose hormonal contraception after liver transplantation. Transplant Proc. 2007;39:1530–1532
  170. Sibanda N, Briggs JD, Davison JM, et al. Pregnancy after organ transplantation: a report from the UK Transplant pregnancy registry. Transplantation. 2007;83:1301–1307

PII: S0011-5029(08)00039-4

doi: 10.1016/j.disamonth.2008.03.003

Disease-A-Month
Volume 54, Issue 7 , Pages 486-507 , July 2008

Article Tools